Transpara®在 SBI展示了包括乳腺密度评估和时间对比在内的创新 FDA认证的乳腺 AI功能，以提升放射科医生的表现-动脉网

Transpara® Showcases Innovative FDA Cleared Breast AI Capabilities including Breast Density Assessment and Temporal Comparison to Elevate Radiologist Performance at SBI

CISION 等信源发布 2025-04-16 21:01



可切换为仅中文







Research being Presented at SBI Demonstrates Industry-leading Performance for the Most-Validated AI for Mammography on the Market

在SBI上展示的研究表明，市场上经过最充分验证的乳腺X光人工智能系统具有行业领先的性能。

COLORADO SPRINGS, Colo.

科罗拉多斯普林斯，科罗拉多州

，

April 16, 2025

2025年4月16日

/PRNewswire/ --

ScreenPoint Medical

医疗屏幕点

will showcase innovative new capabilities of its industry leading Breast AI, Transpara®, at the 2025 Society of Breast Imaging Symposium,

将在2025年乳腺影像学会研讨会上展示其行业领先的乳腺人工智能Transpara®的创新新功能，

April 24-27, 2025

2025年4月24日至27日

(Booth #330). The most clinically validated AI for breast cancer detection on the market, Transpara provides radiologists with a 'second pair' of eyes to help detect cancers earlier and reduce recall rates.

（展位#330）。Transpara 是市场上经过最多临床验证的乳腺癌检测 AI，它为放射科医生提供了“第二双眼睛”，帮助更早发现癌症并降低召回率。

ScreenPoint will highlight its latest advancements, including Transpara 2.1, an update and improved breast cancer detection d algorithm that further refines Transpara's industry-leading performance. This includes compatibility with options for breast density (BI-RADS like and volumetric) and temporal comparison with multiple prior exams.

ScreenPoint将重点展示其最新进展，包括Transpara 2.1——这一更新改进的乳腺癌检测算法进一步提升了Transpara行业领先的性能。其中包括对乳腺密度选项（如BI-RADS和体积密度）的兼容性，以及对多次既往检查的时间对比功能。

This robust temporal comparison capability will be the first of its kind in the market, and will allow suspicious areas on a current study to be analyzed against up to 3 priors over 6 years. The Transpara 2.1 algorithm is both CE-marked and FDA cleared..

这种强大的时间对比功能将是市场上同类产品中的首创，可以将当前研究中的可疑区域与过去六年的多达三项前期研究进行分析对比。Transpara 2.1算法既获得了CE标志认证，也通过了FDA审批。

'We are excited about the significant improvement of Transpara performance when priors are used, especially when more priors with a longer time interval are included, which is in line with radiologists' experience. Our solution is designed for screening and diagnostic use to truly improve clinical workflow,' said Professor .

“当我们使用先前的影像资料时，Transpara 性能的显著提升让我们感到非常兴奋，尤其是当包含更多时间间隔较长的先前影像资料时，这与放射科医生的经验是一致的。我们的解决方案旨在用于筛查和诊断，从而真正改善临床工作流程，”教授表示。

Nico Karssemeijer

尼科·卡尔塞迈尔

, PhD, co-founder and Chief Scientific Officer of ScreenPoint Medical.

，博士，ScreenPoint Medical 的联合创始人兼首席科学官。

The clinical and workflow benefits of Transpara for improving the mammography screening process are the subject of several presentations by

Transpara 在改善乳腺X线摄影筛查流程方面的临床和工作流程优势是几次演讲的主题，这些演讲由

Alejandro Rodriguez Ruiz

亚历杭德罗·罗德里格斯·鲁伊斯

, PhD and Dr.

，博士和博士

Rachel F. Brem

蕾切尔·F·布雷姆

at SBI:

在SBI：

In the study, 'Validation of a Novel Image-based AI Breast Cancer Risk Model for Mammography Screening,' (

在研究《用于乳腺X光筛查的新型基于图像的AI乳腺癌风险模型的验证》中，(

Thursday, April 24, 2025

2025年4月24日，星期四

, 2:45 –

，2:45 –

3:45 PM

下午3点45分

), researchers validated the performance of Transpara Risk, an image-based AI breast cancer risk model. Results showed high risk assessment performance and robustness across screening sites and imaging system vendors and could potentially be used to support personalized breast cancer screening strategies by selecting high-risk women for supplemental imaging..

研究人员验证了基于图像的AI乳腺癌风险模型Transpara Risk的性能。结果表明，该模型在筛查地点和成像系统供应商之间表现出较高的风险评估性能和稳健性，有望通过筛选高风险女性进行补充成像，来支持个性化的乳腺癌筛查策略。

The study 'Multi-site Validation of a Novel AI System for Cancer Detection in Abbreviated Breast MRI,' (

该研究《多中心验证一种新型人工智能系统在简化乳腺磁共振成像中进行癌症检测的效能》，

Thursday, April 24, 2025

2025年4月24日，星期四

, 2:45 –

，2:45 –

3:45 PM

下午3点45分

), validated the performance of AI for breast cancer detection in abbreviated DCE-MRI across multiple institutions. Results showed that the AI system for abbreviated DCE-MRI shows potential for decision support in detecting breast cancer and particularly for accurate identification of very likely normal exams..

），验证了在多家机构中使用简化DCE-MRI进行乳腺癌检测的人工智能性能。结果显示，用于简化DCE-MRI的人工智能系统在乳腺癌检测决策支持方面具有潜力，尤其在准确识别极可能正常的检查方面表现出色。

'Practical and Pro Tips for Incorporating AI into Your Practice' with Rachel F. Brem, MD, FACR, FSBI, Director, Breast Imaging and Imaging,

《将人工智能融入您的实践中的实用与专业建议》Rachel F. Brem，医学博士，FACR，FSBI，乳腺影像与影像科主任

George Washington University

乔治华盛顿大学

(

Saturday, April 26, 2025

2025年4月26日，星期六

，

9:15 AM - 9:40 AM

上午9点15分 - 上午9点40分

), will review practical considerations on why, how and when to implement AI into your breast clinical practice.

），将回顾在乳腺临床实践中为什么、如何以及何时实施人工智能的实际考虑因素。

With 35+ peer-reviewed publications, Transpara is the only breast AI algorithm evaluated in large-scale real-world screening populations multiple times (including

拥有35篇以上的同行评审出版物，Transpara是唯一一个在大规模真实世界筛查人群中多次评估的乳腺AI算法（包括

UCLA

加州大学洛杉矶分校

, Capital Region of

，首都地区

Denmark

丹麦

，

Lund

隆德

University in

大学位于

Sweden

瑞典

, Norwegian Cancer Registry, Reina Sofia Hospital Cordoba). Results of the

，挪威癌症登记处，雷纳索菲亚医院科尔多瓦）。结果

MASAI trial,

MASAI 试验，

demonstrate that Transpara-assisted workflow increased cancer detection by 29% and resulted in a 44% reduction in the screen-reading workload for radiologists.

表明Transpara辅助工作流程使癌症检测增加了29%，并使放射科医生的阅片工作量减少了44%。

About ScreenPoint Medical

关于ScreenPoint Medical

ScreenPoint Medical translates cutting edge machine learning research into technology accessible by radiologists to improve screening

ScreenPoint Medical 将前沿的机器学习研究转化为放射科医生可用的技术，以改进筛查。

workflow

工作流程

, decision

，决定

confidence

信心

and breast cancer

乳腺癌

risk assessment

风险评估

. Transpara is trusted by radiologists globally because it has been developed by experts in machine learning and image analysis and updated with user feedback from world-renowned breast imagers. See all the proof at:

Transpara 受到全球放射科医生的信任，因为它由机器学习和图像分析领域的专家开发，并根据世界知名的乳腺成像专家的用户反馈进行更新。查看所有证据请访问：

https://screenpoint-medical.com/evidence/

Logo -

标志 -

https://mma.prnewswire.com/media/1582198/ScreenPoint_Medical_Logo.jpg

SOURCE ScreenPoint Medical

源 ScreenPoint 医疗

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

发布在PRNEWSWIRE.COM上？

440k+